Medical/Pharmaceuticals
Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022
* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, ...
2022-11-07 21:00
2920
Ainos Reports Unaudited Third Quarter 2022 Financial Results
Revenues increased by 384% year over year Debt ratio decreased to 7% from 75% at year-end 2021 SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose ...
2022-11-07 20:30
2913
Cordis promotes Alan Tsai as GM Greater China
SHANGHAI, Nov. 7, 2022 /PRNewswire/ -- From November 1, 2022, Mr. Alan Tsai is promoted to the role of General Manager of Cordis Greater China. He will head the leadership team responsible for strategic planning, business operation and team development forGreater China, the fastest growing area i...
2022-11-07 18:06
1981
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting
- Poster with updated Phase Ib TOUCH results suggest selinexor plus GemOx could provide a therapeutic option for heavily pre-treated Stage III/IV patients with relapsed/refractory (R/R) T and NK-cell lymphoma - Online abstract with results from the open-label LAUNCH study demonstrated the encoura...
2022-11-07 14:38
2459
Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial
SHANGHAI, Nov. 6, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that Hexvix®, a drug used for the diagnosis for bladde...
2022-11-07 10:04
1991
China Marches into the Era of Interventional Direct Annuloplasty
Launching of the 1st Human Implantation of "DragonRing" – Catheter-based Mitral Annuloplasty Device HANGZHOU, China, Nov. 5, 2022 /PRNewswire/ -- On October 28, 2022, a multidisciplinary, and international cardiac team led by ProfessorMao Chen from Department of Cardiology, West China Hospital,S...
2022-11-06 01:44
3882
Certa Therapeutics' investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
* Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data * The research demonstrated that treatment with FT011 results in a remarkable...
2022-11-04 20:00
3231
Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC
HONG KONG, Nov. 3, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced the patient enrollment completion for the Phase III clinical trial of Ivonescimab (PD-1/VEGF bi-specific antibody, AK112) combined with chemotherapy for the treatment of EGFR-mutant locally advanced or metasta...
2022-11-04 08:57
2346
ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting
SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the initial results from a global Phase II st...
2022-11-04 03:33
3409
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting
SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results from three studies of ...
2022-11-04 03:32
2752
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharm...
2022-11-03 21:10
2956
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and ...
2022-11-03 21:01
3144
Yuyu Pharma attendance at European Pharmaceutical Conference
SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ -- Robert Yu, CEO of Yuyu Pharma,
has been attending biopharmaceutical conferences held inGermany, BIO-Europe and
CPHI. The purpose is to explore opportunities to expand into international
markets, such as Europe.
2022-11-03 21:00
3931
Zhongchao Inc.'s China Operating Entity, Chongqing Xinjiang Pharmaceutical Co., Ltd. Obtained Pharmaceutical Trade and Medical Device Operation Licenses, Ready to Enter Into Pharmaceuticals Circulation Market
SHANGHAI, Nov. 3, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that one of theChina operating entities of which the Company cons...
2022-11-03 19:30
2600
Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation
The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...
2022-11-03 19:00
2186
Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004
BOSTON and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2 diabetes mell...
2022-11-03 13:11
2875
Shanghai Operation Robot announced the first Robot-assisted human clinical trial of biliary stent placement surgery
SHANGHAI, Nov. 2, 2022 /PRNewswire/ -- Shanghai Operation Robot Co.,Ltd announced the results of its initial clinical trial of ERCP (Endoscopic retrograde cholangiopancreatography) robot in biliary stent placement surgery. It is the first Robot-assisted human clinical trial of biliary stent place...
2022-11-02 13:55
2316
WAT Medical Entrusted By Geely Auto To Develop Neuromodulation Technologies To Improve Travel Experiences
VANCOUVER, BC, Nov. 1, 2022 /PRNewswire/ -- With the foreseeable increase in outdoor travelling in the near future, as well as the ever-expanding prospects of self-driving vehicles that have been reported to increase the incidence of nausea and vomiting, motion sickness is becoming a continuously...
2022-11-02 01:15
2956
Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)
* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA * Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups * Software ...
2022-11-01 22:00
3244
New Randomized Controlled Study Published in JAMA Demonstrates the Value of Clinical Decision Support Tools in Preventing Acute Kidney Injury in Patients Undergoing Coronary Angiography
– Researchers used Terumo Health Outcomes' ePRISM® software to calculate safe
contrast volume targets and improve overall patient outcomes –
SOMERSET, N.J., Nov. 1, 2022 /PRNewswire/ -- A new study published in JAMA
2022-11-01 20:00
2408
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
RoboParty Unveils RP1, a High-Performance Full-Stack Open-Source Humanoid Robot at IROS
2026-10-04 00:56
10671
Nuix Neo Generative AI Framework
2026-10-08 08:02
9102
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8125
